Chiome Bioscience Inc.

Chiome Bioscience Inc. is a biotechnology company that engages in the research, development, and commercialization of innovative therapeutic solutions, focusing on the development of antibody-based drugs. Established in Japan, the company operates within the highly specialized bio-pharmaceutical sector. Chiome Bioscience is renowned for its proprietary ADLib® system, an antibody generation platform that facilitates the discovery and development of novel monoclonal antibodies, particularly those targeting cancer and autoimmune diseases. By leveraging state-of-the-art biotechnology techniques, the company aims to address unmet medical needs and improve disease management worldwide. Chiome Bioscience's work is crucial in the advancement of next-generation antibody therapies, making it a significant player in the global biopharmaceutical market. Through collaborative partnerships and its cutting-edge research, the company continues to make impactful contributions to scientific innovation and healthcare solutions.